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Abstract: Clostridium difﬁ  cile infections (CDI) have increased in frequency throughout the 
world. In addition to an increase in frequency, recent CDI epidemics have been linked to a 
hypervirulent C. difﬁ  cile strain resulting in greater severity of disease. Although most mild to 
moderate cases of CDI continue to respond to metronidazole or vancomycin, refractory and 
recurrent cases of CDI may require alternative therapies. This review provides a brief overview 
of CDI and summarizes studies involving alternative antibiotics, toxin binders, probiotics, and 
immunological therapies that can be considered for treatment of acute and recurrent CDI in 
severe and refractory situations.
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Overview of CDI
Clostridium difﬁ  cile (C. difﬁ  cile) is an anaerobic, Gram-positive, spore-forming bacillus 
that is known to cause associated diarrhea and pseudomembranous colitis. C. difﬁ  cile 
infection (CDI) is a serious medical condition, and although heightened awareness of CDI 
outbreaks has increased surveillance, it appears that the incidence and severity of CDI is 
increasing around the world (Surowiec et al 2006; Owens 2007). C. difﬁ  cile is reported 
to cause up to one-third of antibacterial-associated diarrhea cases, 50%–75% of all cases 
of antibiotic-associated colitis, and 90%–100% of antibiotic-associated pseudomembra-
nous colitis cases (Aslam et al 2005; Owens 2007). Mortality of CDI, as either a direct 
or indirect cause of death, is quite signiﬁ  cant approaching 17% in one trial (Pepin et al 
2005). In addition, the cost of hospitalization and treatment of CDI is also signiﬁ  cant. It 
is estimated that the average cost of treatment per case of CDI is about US$4000 with an 
average increase in hospital stay of 3.6 days (Aslam et al 2005; Jodlowski et al 2006).
Clinical disease associated with C. difﬁ  cile has a wide range of clinical features 
(Mylonakis et al 2001). Individuals may be colonized with toxin-producing strains of 
C. difﬁ  cile and become asymptomatic carriers, or manifest symptoms. Toxin-producing 
strains of C. difﬁ  cile are carried by 7%–11% of hospitalized inpatients, 5%–7% of 
those in long-term care facilities, and 2% or fewer of ambulatory adults (Poutanen 
et al 2004). In neonates, the carriage rate is much higher, approaching 70% (Kelly CP 
et al 2004; Poutanen et al 2004). Although neonates are common carriers of C. dif-
ﬁ  cile, they seldom develop pseudomembranous colitis unless they are suffering from 
concomitant gastrointestinal motility disorders or other conditions such as neutropenia 
that increase risk (Kelly et al 2004). Neonatal resistance to C. difﬁ  cile is thought to 
be primarily related to the inability of toxins to attach to the mucosa of newborns, or 
protection from the toxins by maternally-acquired antibodies. Carrier rates of neonates 
drop to levels similar to adults by age 3.
In those developing disease, clinical symptoms vary from mild diarrhea to life-
threatening colitis, toxic megacolon, and sepsis (Owens 2007). Most often, clinical Therapeutics and Clinical Risk Management 2008:4(5) 950
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features of CDI include mild to moderate non-bloody diarrhea, 
with some abdominal cramping and tenderness. In those with 
severe CDI, profuse watery diarrhea, abdominal pain, fever, 
nausea, anorexia, and malaise are frequently seen. In addition, 
leukocytosis, elevated C-reactive protein, and low albumin 
levels are often present in severe CDI (Monaghan et al 2008).
Early diagnosis is an essential aspect of managing CDI. 
A diagnosis of CDI should be considered in patients with an 
unformed stool and characteristic odor who have received 
antibiotics within the previous couple of months and/or 
those with diarrhea arising  72 hours after admission to a 
healthcare facility (Bartlett et al 2008). A diagnosis of CDI 
is conﬁ  rmed with a positive stool test or the presence of 
pseudomembranes (Cohen et al 2007).
The pathogenesis of disease associated with C. difﬁ  cile is 
quite complex. C. difﬁ  cile colitis results from a disruption of 
normal bacterial ﬂ  ora of the colon, ingestion of C. difﬁ  cile, 
and the release of toxins that lead to mucosal damage and 
inﬂ  ammation. Although it is not known why some individuals 
do not develop disease, it is understood that toxin produc-
tion is essential for disease to occur. C. difﬁ  cile produces 
two primary toxins capable of causing colitis: enterotoxin 
(toxin A), the more potent of the two toxins, and cytotoxin 
(toxin B) (Surowiec et al 2006; Cloud et al 2007; Durai 
2007). These toxins trigger the attraction and adhesion of 
neutrophils resulting in inﬂ  ammation of the mucosal lining, 
and cellular necrosis, as well as increased peristalsis and 
capillary permeability, leading to diarrhea and colitis (Durai 
2007). A strain of C. difﬁ  cile, designated North American 
pulsed-ﬁ  eld gel electrophoresis type 1 (NAP 1), has been 
linked to several outbreaks of severe disease in North 
America and Europe. NAP 1 is known to produce 16 times 
more toxin A and 23 times more toxin B than other strains, 
as well as an additional toxin known as binary toxin (Kuijper 
et al 2006). NAP 1 is discussed in more detail in the “Recent 
CDI Outbreaks” section.
The predominant risk factor associated with acquisition 
of C. difﬁ  cile is previous antibiotic use (Bartlett et al 2008). 
In that regard, good antimicrobial stewardship has been an 
important aspect of CDI risk reduction. Of late, however, 
the relationship between CDI and antibiotic exposure has 
been questioned. A recent study of patients with community-
acquired CDI showed that 61% of patients did not admit to 
antibiotic exposure within the previous 90 days of developing 
disease (Dial et al 2005). Further, an additional study found 
that 59% of patients with community-acquired CDI did not 
have documented antibiotic exposure (Kutty et al 2006). 
While all antimicrobial agents have the potential to alter 
colonization and increase risk of CDI, certain antibiotics 
have been linked to CDI more than others and should be used 
with caution (Kuijper et al 2007). Among these agents are 
ﬂ  uoroquinolones, clindamycin and the beta-lactam agents.
Historically, the risk for infection with C. difﬁ  cile has 
been greater in elderly and debilitated patients who have little 
immunity and produce few antibodies against the C. difﬁ  cile 
toxins (Durai 2007). Additional risk factors for CDI may also 
include feeding tube use and use of antiulcer medications, 
although conﬂ  icting data exists (Gerding et al 2008b). Studies 
conducted by Dial and associates have shown proton pump 
inhibitor (PPI) use as a risk factor for CDI (Dial et al 2005). 
PPIs have also been identiﬁ  ed as an independent risk factor 
for CDI by other investigators, but not shown as a risk factor 
in some trials as well (Gerding et al 2008b). Until additional 
information is gathered through clinical studies, clinicians 
are encouraged to utilize clinical discretion when considering 
PPI use for their patients.
Prevention of microbial transmission and reduction of 
risk factors upon exposure are primary strategies utilized 
for control of CDI (Owens 2007). Primarily, C. difﬁ  cile is 
spread via a fecal-oral route. If a patient is suspected of being 
infected with C. difﬁ  cile, they should be placed in an isolated 
room or have a dedicated commode (Gerding et al 2008b). If 
it is not possible to isolate patients in single rooms, such as 
during an outbreak, patients may be placed in cohorts. Thor-
ough cleansing of patient rooms and equipment following 
exposure to symptomatic patients is also essential. C. difﬁ  cile 
is capable of producing highly resistant spores, which are able 
to survive for extended periods of time. Although resistant 
to many disinfectants, cleaning agents containing chlorine 
appear to have some activity against the spores. Disinfection 
with a 1:10 dilution concentration of concentrated sodium 
hypochlorite (ie, bleach) has been shown to be effective 
(Gerding et al 2008b). Vaporized hydrogen peroxide is also 
being studied as an agent for environmental decontamination 
of C. difﬁ  cile spores. In contrast, quaternary ammonium-
based products are not active against spores and may actually 
encourage sporulation. Finally, the use of protective clothing 
(gloves and aprons) and hand hygiene are important aspects 
of CDI prevention.
Diagnosis of CDI
C. difﬁ  cile infection is typically diagnosed by detection of 
the presence of toxin A and/or toxin B in a stool sample. 
C. difﬁ  cile toxin detection by cytopathic effect on cells is 
generally regarded as the best test available for CDI (Bartlett 
et al 2008). This testing methodology takes up to 48 hours to Therapeutics and Clinical Risk Management 2008:4(5) 951
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obtain a result, which is a disadvantage. Currently, most labs 
in the US use enzyme immunoassay (EIA) to detect toxin 
A or toxins A and B (Bartlett et al 2008). EIAs are relatively 
inexpensive, easy to perform, and have a rapid turnaround 
time. An additional immunoassay utilized for diagnosis of 
CDI is the glutamate dehydrogenase (GDH) enzyme test 
(common-antigen test), which rapidly detects the presence 
of C. difﬁ  cile in stool samples (Ticehurst et al 2006). Like a 
culture, the GDH test only detects the presence of C. difﬁ  cile, 
not the production of toxins. Further, GDH is also produced 
by other organisms. In considering these points, the GDH test 
is best utilized as a screening test and coupled with a test for 
the presence of toxins. Enzyme-linked immunosorbent assay 
(ELISA) tests for toxin A or toxins A and B are attractive due 
to rapid turnaround time (about 2 hours) and high speciﬁ  city 
(Monaghan et al 2008). The sensitivity of  ELISA testing has 
been shown to vary widely (79%–97%), however (Manabe 
et al 1995). Given this level of sensitivity, it is prudent to send 
as many as three samples to rule out disease if initial tests are 
negative. Assays which detect toxin A and B are preferable 
since toxin-A negative, toxin-B positive strains of C. difﬁ  cile 
are known to cause disease (Bartlett et al 2008).
Cultures of stool specimens can also be performed 
but require additional testing to determine if the isolated 
C. difficile strain produces toxins (Durai 2007; Owens 
2007). Results are not available for 3–4 days due to the time 
needed to perform the tests, limiting the usefulness of this 
strategy. Cultures are useful when investigating outbreaks of 
C. difﬁ  cile, conducting susceptibility testing for C. difﬁ  cile 
strains, and evaluating emerging testing methods.
Finally, ﬂ  exible sigmoidoscopy can also be utilized to 
aid diagnosis. This more invasive approach is especially 
attractive for patients with suspected CDI but negative stool 
toxin assays (Durai 2007).
Standard therapy for CDI
Treatment recommendations for disease associated with 
C. difﬁ  cile include stopping the precipitating antibiotic 
agents when possible, and providing supportive care by 
administering ﬂ  uids and electrolytes as required (Gerding 
et al 2008al; Surowiec et al 2006). It is important to note 
that antiperistaltic agents (eg, loperamide, atropine, opi-
ates) should not be included, either alone or in combination, 
as a therapeutic modality of CDI as they may predispose 
patients to toxic megacolon (Gerding et al 2008). Anti-
biotics directed against C. difﬁ  cile are a mainstay of CDI 
therapy. Oral vancomycin was the ﬁ  rst antimicrobial agent 
shown effective for treatment of CDI. Following several 
studies that demonstrated treatment equivalence between 
metronidazole and vancomycin, metronidazole emerged 
as the consensus ﬁ  rst-line treatment for patients other than 
pregnant and lactating women, and those intolerant of metro-
nidazole (Aslam et al 2005; Suroweic et al 2006; Durai 2007; 
Owens 2007). The primary reasons for metronidazole becom-
ing the agent of choice for CDI are reduced cost compared 
with that of oral vancomycin and concern that vancomycin 
use could lead to increased spread of vancomycin-resistant 
enterococci. Reports describing metronidazole failures 
and questions of the equivalence of metronidazole and 
vancomycin for CDI have been raised (Musher et al 2005; 
Pepin et al 2005a). Pepin and colleagues recently compared 
metronidazole and vancomycin treatment outcomes in 
patients separated into the time period before identiﬁ  cation 
of the BI/NAP1 epidemic C. difﬁ  cile strain (1991–2002) 
and after the strain was identiﬁ  ed (2003–2006) (Pepin et al 
2007). From 1996 to 2002, patients receiving vancomycin 
demonstrated improved outcomes compared to those 
receiving metronidazole. During the 2003–2006 time period, 
the odds ratio for the comparison between vancomycin and 
metrondizole was 1.0, showing no difference between the 
treatments. If evaluating performance in patients stratiﬁ  ed 
by disease severity, data from clinical trials does suggest, 
however, that vancomycin is superior to metronidazole for 
those with severe disease (Gerding et al 2008a).
Recently revised treatment guidelines for CDI are 
stratified into three groups: mild to moderate disease, 
severe disease (white blood cell count  15,000 cells/mm3 
or creatinine level  1.5 times the level prior to CDI), and 
severe complicated disease (severe disease and admission to 
an intensive care unit, need for colectomy, toxic megacolon, 
ileus, hypotension or, colonic perforation) (Cohen et al 2007). 
For patients with mild to moderate CDI, oral metronidazole 
at a dose of 500 mg 3 times per day is recommended as 
ﬁ  rst-line therapy. Oral vancomycin 125 mg 4 times daily for 
10–14 days is now recommended for severe cases of CDI. 
Finally, for those diagnosed with severe complicated CDI, 
vancomycin 500 mg orally or via nasogastric tube 4 times 
per day and/or intravenous metronidazole 500–750 mg every 
8 hours is recommended. If a patient with severe complicated 
CDI has complete ileus, intravenous metronidazole is used 
with rectal administration of vancomycin.
The latest CDI therapy guidelines also suggest that 
recurrent CDI be treated with the same drug used as initial 
therapy, unless the severity of the infection has increased 
(Cohen et al 2007). Metronidazole should not be used for a 
second recurrence. In CDI patients with a second or greater Therapeutics and Clinical Risk Management 2008:4(5) 952
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recurrence, an oral vancomycin taper, with or without pulse 
dosing, is utilized.
Recent CDI epidemics
As stated above, overall rates of CDI have increased in 
recent years and the number of severe cases has increased 
as well (Aslam and Musher 2006; Kuijper et al 2006; Owens 
2007). Although the exact reason for the increase is not 
fully understood the discovery of a highly virulent strain 
of C. difﬁ  cile has been associated with recent outbreaks 
(Kuijper et al 2006). In 2002, a C. difﬁ  cile epidemic occurred 
in hospitals in Quebec, Canada (Warny et al 2005). The out-
break was primarily caused by a C. difﬁ  cile strain identiﬁ  ed 
as a toxinotype III. This strain was further identiﬁ  ed and 
genotyped through pulse-ﬁ  eld gel electrophoresis (PFGE) 
and PCR-ribotyping and classiﬁ  ed as a North American 
PFGE type 1 (NAP1) and PCR-ribotype 027. In vitro data 
showed this particular strain, NAP1/027, to produce 16 times 
the amount of toxin A and 23 times the amount of toxin B, 
compared to a control strain, toxinotype 0. The NAP1/027 
strain has also shown greater spore producing capacity 
compared to strains not associated with CDI outbreaks 
(Owens 2007). In addition to the outbreaks in Canada, 
NAP1/027 has been associated with recent outbreaks in the 
US, Netherlands, and UK (Warny et al 2005; McDonald et al 
2005). A hypervirulent PCR-ribotype 027 strain was associ-
ated with outbreaks in Belgium and France (Kuijper et al 
2006; Cookson 2007). Although these particular strains were 
not speciﬁ  cally mentioned as being identiﬁ  ed as NAP1 it has 
been proposed that all ribotype 027, toxinotype III strains 
belong to this PFGE group (Kuijper et al 2006). Of note, the 
NAP1/027 strain exhibits increased resistance to the ﬂ  uo-
roquinolone antibiotics and a cohort study of the epidemic 
at one Quebec hospital identiﬁ  ed prior ﬂ  uoroquinolone use 
as the antibiotics most highly correlated with the develop-
ment of CDI (Pépin et al 2005b). It has been proposed that 
the widespread use of ﬂ  uoroquinolones has also lead to the 
selection of the resistant strain and contributed to outbreaks 
in the US (McDonald et al 2005).
A follow-up ﬁ  nding of the epidemic in a Quebec hospital 
showed that vancomycin was not superior to metronidazole 
in reducing post-infection complications from 2003 to 2006 
(Pépin et al 2007). This was in contrast to a prior study 
conducted at the same hospital from 1991 to 2003 in which 
vancomycin demonstrated the ability to decrease complica-
tions vs metronidazole for CDI (Pépin et al 2004; Pépin 
et al 2007). The hypervirulent strain, which was suspected 
to arrive at the institution in 2003, might account for this 
difference (Pépin et al 2007). It has been proposed that due 
to the increased amounts of toxin produced by the hyper-
virulent strain, antibiotics such as vancomycin, which takes 
approximately 24 hours to arrive at the colon, do not work 
quickly enough to prevent the toxins from saturating binding 
sites in the colon. The antibiotics still may be utilized to con-
trol further damage by reducing C. difﬁ  cile producing toxin 
contained in the intestine; however, the toxin already bound 
and causing intestinal inﬂ  ammation will be dependent on the 
immune system. Although more data are needed to conﬁ  rm 
this hypothesis, it reinforces the need for the development 
of preventative procedures or agents having a quick onset of 
action. Therapies such as toxin-binding medications, immun-
globulins or a vaccine are potential strategies that should be 
investigated to control this aggressive strain.
Relapse rates and resistance
Recurrence rates of CDIs have typically ranged from 5% to 
20%; however, Musher et al (2005), described 50% of the 
subjects tested as being refractory to treatment or having 
either documented or clinical recurrence of disease (Musher 
et al 2005; Segarra-Newnham 2007). C. difﬁ  cile resistance 
to metronidazole or vancomycin therapy has been theorized 
as a reason for treatment failures, however current data 
does not support this theory (Surowiec et al 2006). Unfor-
tunately, regular susceptibility testing of C. difﬁ  cile strains 
is not conducted in microbiology laboratories, as C. difﬁ  cile 
is generally considered to be susceptible to metronidazole 
and vancomycin (Peláez et al 2002). Although documented 
widespread susceptibility data are limited, resistant cases 
have been reported and documentation of this phenomenon is 
important (Peláez et al 2002; Kuijper et al 2006). Peláez and 
colleagues (2002) conducted C. difﬁ  cile susceptibility tests 
over an eight-year period and reported 6.3% of isolates as 
resistant to metronidazole (minimum inhibitory concentration 
[MIC]   32 μg/mL), 3.1% of isolates intermediately resistant 
(MIC 4–16 μg /ml) to vancomycin and 0 isolates resistant 
to vancomycin (MIC   32 μg/mL) (Peláez et al 2002). The 
rates of resistance were higher in the HIV infected popula-
tion, perhaps explained by the likely increased prior use of 
the antimicrobial drugs in these patients.
Although the reported resistance may bring about general 
concern, the clinical signiﬁ  cance of these reports is unknown. 
MIC breakpoints are not established for colonic concentra-
tions and it is possible that the concentrations reached at the 
local site would be high enough to overcome and effectively 
treat the resistant strains (Peláez et al 2002). Other data in 
which treatment failures to metronidazole were reported as Therapeutics and Clinical Risk Management 2008:4(5) 953
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high as 50% suggest that antimicrobial resistance did not play 
a part in the treatment failures based on the lack of any isolate 
at the institution being identiﬁ  ed as resistant (Musher et al 
2005). Another issue needing further analysis is the effect 
the hypervirulent strain associated with recent epidemics will 
have on treatment failures. In the recent Quebec outbreak, 
during 2003–2004 the hypervirulent strain was associated 
with an increase in recurrent infections after treatment with 
either vancomcyin or metronidazole when compared to recur-
rent infection rates from 1991 to 2002 (Pepin et al 2005b; 
Pepin et al 2007). However, the recurrence rate decreased in 
the following years (2005–2006) prompting the researchers to 
suspect the recurrences were due to reinfection from contin-
ued exposure vs actual relapse (Pepin et al 2007). The reason 
for reinfections was estimated by the total number of new 
hospital-acquired CDIs during this time. The number of new 
cases from 1991 to 2002 ranged from 37 to 65, but increased 
in 2003 to 303, and further increased in 2004 to 363. In 2005, 
the number of new cases declined to 173 and only 54 cases 
were documented halfway through 2006. The researchers 
further proposed that increased used of sporicidal cleaners 
in patients’ rooms during the hospitalization rather than only 
upon discharge may reduce the recurrence rate of CDI.
Although it is difﬁ  cult to precisely determine the cause 
of the increasing rates and severity of CDI, it is likely due 
to a combination of factors. The continued use of antibi-
otics known to increase the risk for CDI (beta-lactams, 
clindamycin, and more recently fluoroquinolones), the 
recent appearance of a hypervirulent strain, as well as other 
environmental factors all likely contribute to the increased 
incidence. Increased awareness of the complications and 
outbreaks of CDIs may increase surveillance, which further 
increases the reported rates of CDIs. Due to the increasing 
number of overall and severe cases of CDI and reported treat-
ment failures with current agents, there is a need for more 
effective therapeutic treatment options as well as preventative 
treatments. Current research involves treatment of acute 
disease, as well as treatment and prevention of recurrent 
disease. The following sections provide an overview of new 
discovery involving various agents being evaluated for acute 
and recurrent CDI.
Adjunctive and alternative 
therapeutic options for CDI
The literature was reviewed for alternative and investiga-
tional agents. The majority of the agents investigated for CDI 
fall into the following categories: antimicrobial agents, toxin 
binding agents, immune modifying agents and probiotics. 
Although many agents have in vitro data, this discussion will 
focus primarily on those products that have human clinical 
trials. Currently, only in vitro data has been published for 
XRP 2868, telavancin (TD-6424), daptomycin, rifalazil, 
lacticin 3147, and tinidazole (Bannatyne and Jackowski 
1987; Goldstein et al 2003; Rothstein et al 2003; Anton 
et al 2004; Goldstein et al 2004; Citron et al 2005; Fung 
and Doan 2005; Goldstein et al 2005; Tyrrell et al 2006; 
Hecht et al 2007; Rea et al 2007). Tinidazole is a structural 
analogue of metronidazole and like metronidazole has 
good in vitro activity against C. difﬁ  cile (Fung and Doan 
2005). A unique and promising ﬁ  nding is that tinidazole 
was recently found to have low minimum inhibitory con-
centrations against six NAP1 strains (Hecht et al 2007). 
Even though promising clinical trials were performed with 
bacitracin, no recent evidence has been published regarding 
its use in CDI (Young et al 1985; Dudley et al 1986).
Antimicrobial agents
Ramoplanin
As a lipoglycodepsipeptide antibiotic, ramoplanin has 
demonstrated activity against aerobic and anaerobic gram-
positive bacteria such as Enterococcus and C. difﬁ  cile (Farver 
et al 2005; Fulco and Wenzel 2006). Its bactericidal activity 
is by blocking peptidoglycan synthesis by binding to lipid 
II. Lack of cross-resistance with ramoplanin to vancomycin 
has been proposed due to its unique mechanism of action. 
High concentrations of ramoplanin have been observed in 
the feces. In vitro and in vivo hamster gut evaluations have 
shown that ramoplanin has similar efﬁ  cacy in reducing cyto-
toxin production compared to vancomycin but may be more 
effective in killing spores and preventing spore recrudescence 
(Freeman et al 2005). Oscient Pharmaceuticals, the developer 
of ramoplanin, has stated that the antibiotic has FDA Fast 
Track status and Special Protocol Assessment for Phase III 
trials (Oscient Pharmaceuticals 2007).
A Phase II trial evaluated the efﬁ  cacy of ramoplanin 
to that of vancomyin in the treatment of hospital acquired 
CDI (Pullman et al 2004). As a multi-centered, randomized, 
open-label, 3 arm trial, patients received either ramoplanin at 
200 mg twice a day (n = 28) or 400 mg twice a day (n = 29) 
for 10 days or vancomycin 125 mg 4 times a day (n = 29) for 
10 days. An end-of-therapy assessment evaluated the clinical 
response as a complete cure or partial resolution of symp-
toms. The end-of-therapy clinical cure was 83% in patients 
receiving ramoplanin 200 mg and 85% in the ramoplanin 
400 mg group as compared to 86% in the vancomycin group. 
The rate of relapses was 26.3% with the ramoplanin 200 mg Therapeutics and Clinical Risk Management 2008:4(5) 954
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group, 21.7% with the ramoplanin 400 mg group and 20.8% 
with the vancomycin treated group. Common adverse effects 
associated with ramoplanin were nausea (22.8%), vomiting 
(14.1%) and diarrhea (10.5%). Serious adverse effects with 
ramoplanin were respiratory failure, gastrointestinal bleeding, 
angina, aspiration, hypoxia, ileus, pancreatitis, proctitis, small 
bowel obstruction, emesis, sepsis and cholelithiasis but these 
were similar to that of the vancomycin treated group. The seri-
ous adverse effects related to vancomycin use were respiratory 
failure, aspiration, hypoxia, gastrointestional hemorrhage, 
deep venous thrombosis, aortic stenosis, cardiac failure, car-
diogenic shock, multiple-organ failure, pyrexia, and sickle 
cell anemia crisis. The mortality rate was similar between 
the treatment groups and deaths were not attributed to the 
medications. The authors stated that ramoplanin demonstrated 
acceptable efﬁ  cacy with limited toxicity but there was insuf-
ﬁ  cient power to establish non-inferiority to vancomycin.
Rifaximin
Rifaximin is a poorly absorbed rifamycin derivative, which 
acts by inhibiting bacterial RNA synthesis (Marchese et al 
2000). It is active against gram-negative and gram-positive 
anaerobic and aerobic bacteria. The drug is used primarily 
for travelers’ diarrhea (Gerard et al 2005). Based on the 
available information rifaximin appears to be safe and 
well tolerated and lack any clinically signiﬁ  cant CYP3A4 
drug interactions. Encouraging results on in vitro data for 
rifaximin were recently published by Hecht et al (2007). They 
tested 110 isolates of C. difﬁ  cile collected from 1983–2004. 
Rifaximin was one of the most active agents tested with 
lower minimum inhibitory concentrations than other agents. 
However, three of the isolates demonstrated resistance (high 
MICs). Two of the isolates were from Argentina in 1998 
and 1 was from Chicago in 1995. This does raise the concern 
about possible clinical implications if resistance became 
more widespread. Six of the isolates that had low MICs 
were of the NAP1 type (implicated in recent outbreaks), 
and thus rifaximin may be a potential treatment option in 
such situations.
In a small clinical trial of twenty patients, nine of ten 
patients who received rifaximin 200 mg three times a day 
for 10 days were successfully treated (Boero et al 1990). In 
the vancomycin group ten of ten patient receiving 500 mg 
twice daily for 10 days were successfully treated.
In one case report rifaximin, vancomycin and a probiotic 
were found successful in treating a refractory case of CDI 
(Berman 2007). The patient required several courses of this 
combination for a total of seven weeks to achieve resolution 
of his symptoms. Initially the probiotic used was Culturelle® 
(ConAgra Functional Foods, Inc, Omaha, NE, USA) but 
in the later courses was changed to Flora-Q (Kenwood 
Threapeutics, Fairﬁ  eldd, NJ, USA). Culturelle® contains 
Lactobacillus rhamnosus GG (LGG) (Amerifit Brands 
Inc. 2008). Flora-Q® contains Lactobacillus acidophilus, 
Biﬁ  dobacterium, Lactobacillus paracasei, Streptococcus 
thermophilus (Kenwood 2008). Jadlowski and collegues 
(2006) also reported successful use of rifaximin to treat CDI 
in patients who were unable to take other agents or had failed 
with other agents (Jadlowski et al 2006).
Recently Johnson and colleagues (2007) published a 
series on 8 women with recurrent CDI (Johnson et al 2007). 
Patients received a 14-day course of oral rifaximin immedi-
ately following a course of vancomycin while asymptomatic. 
Six of the 8 patients received rifaximin at a dose of 400 mg 
orally twice daily. In the remaining 2 patients, 1 received 
200 mg orally 3 times a day and 1 received 200 mg orally 
twice a day. Seven of the patients had no further episodes 
of diarrhea after 1 course of rifaximin. One patient did 
require a second 14-day course of rifaximin to resolve the 
diarrhea. This patient was also found to have a C. difﬁ  cile 
isolate still present after her second treatment and the isolate 
demonstrated resistance by having a high MIC. The authors 
were concerned about the potential for resistance based on 
this ﬁ  nding. However, 1 study found a low incidence of 
spontaneous development of rifaximin-resistant organisms 
(Marchese et al 2000).
A study is currently being conducted by Salix Pharmaceu-
ticals to evaluate rifaximin for CDI (Salix Pharmaceuticals 
2007a). It is a phase III clinical trial assessing the safety and 
efﬁ  cacy of rifaximin compared to vancomycin. An estimated 
300 patients will be enrolled in this trial. In a May 2007 news 
release Salix Pharmaceuticals anticipated a new drug applica-
tion for CDI by mid 2008 (Salix Pharmaceuticals 2007b).
Nitazoxanide
Nitazoxanide is a nitrothiazolide antiparasitic used to treat 
cryptosporidiosis and giardiasis (McVay and Rolfe 2000). Its 
mechanism of action is to interfere with pyruvate-ferredoxin 
oxidoreductase enzyme-dependent electron transfer reaction, 
which is necessary for anaerobic metabolism. The inhibition 
of C. difﬁ  cile occurs with low concentrations of nitazoxanide 
or with its metabolite, tizoxanide (Musher et al 2006).
Nitazoxanide was compared to metronidazole in a 
prospective, randomized, double-blind study of hospitalized 
patients with CDI (Musher et al 2006). The primary endpoint 
was deﬁ  ned as normal bowel habits and no other clinical Therapeutics and Clinical Risk Management 2008:4(5) 955
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symptoms after 7 days of treatment. The response rate was 
36/40 (90%) patients with the 7-day course of nitazoxanide, 
32/36 (88.9%) with the 10-day course of nitazoxanide and 
28/34 (82.4%) with metronidazole. The sustained response 
rate was not statistically signiﬁ  cant between the treatment 
groups at 31 days.
A double-blind, randomized study evaluated patients 
who had failed conventional therapy of metronidazole 
and/or oral vancomycin for C. difﬁ  cile colitis (Musher 
et al 2007). Failure was deﬁ  ned as a persistence of fever, 
diarrhea, abdominal pain, unexplained leucocytosis and a 
positive EIA for C. difﬁ  cile toxin after 14 days of treat-
ment or at least two infections that responded to treatment 
but recurred within 30 days. Patients received either 
nitazoxanide 500 mg orally twice a day for 10 days or met-
ronidazole. The study results were revealed after 22 patients 
and an additional open label study followed with 13 patients 
receiving nitazoxanide after conventional therapy failure. 
The results were that 74% (26/35 patients) had rapid 
resolution of symptoms with nitazoxanide. Twenty out of 
the 28 patients (71%) with persisting infection after failure 
to metronidazole responded and 6/7 patients (86%) with 
recurrent disease responded to nitazoxanide (p = 0.65). 
The major study limitation was that it was open labeled 
and non-comparative.
OPT-80
OPT-80, also known as PAR-101 and tiacumicin B, is 
a macrocylic antibiotic. As a member of the tiacumicin 
family, OPT-80 is an antibiotic naturally produced by 
Dactylosporangium aurantiacum. The spectrum of activity 
is against gram-positive aerobic and anaerobic bacteria 
including C. difﬁ  cile (Ackerman et al 2004). Phase I clinical 
trials have reported minimal absorption of OPT-18 and 
high concentrations in the feces when administered orally 
(Johnson 2007).
A phase II open-label, dose-ranging study evaluated 
45 adults receiving either 50, 100, or 200 mg of OPT-18 
every 12 hours for 10 days (Johnson 2007). The results were 
that the higher doses were more efﬁ  cacious in the median 
time-to-cessation of diarrhea. Two patients had recurrence of 
symptoms. Another phase II trial was an open-label, proof-
of-principle study of  32 patients receiving 50, 100, or 200 mg 
every 12 hours of OPT-18 for 10 days. The conclusion was that 
the C. difﬁ  cile counts decreased by day 10 in all but one patient. 
Adverse effects were unrelated to the drug in both trials.
Phase III clinical trials are ongoing to access the cure rate 
and rate of recurrence of OPT-18 as compared to vancomycin 
in randomized, double-blind studies. Completion of the trials 
is anticipated in March 2008 (Johnson 2007).
Fusidic acid
Fusidic acid, also known as fucidin, is in the class of poly-
saccharides commonly referred to as sulfated fucans. The 
antibacterial action of fusidic acid is by inhibiting protein 
synthesis with preventing translocation on the ribosome. 
Its current use is in treating staphylococcal infections. (Leo 
Pharmaceutical, Medsafe). Adverse effects reported have 
been primarily gastiointestinal with rare cases of skin rashes 
and hematologic disorders. Drug-drug interactions to with 
fusidic acid include; antibiotics that are biliary excreted, oral 
anticoagulants, and HMG-CoA reductase inhibitors.
Barreti et al (2007) proposed that fusidic acid is consid-
ered to be an L-selectin blocker when inhibiting C. difﬁ  cile. 
The proposed mechanism of action is by inhibiting L-selectin, 
which is an adhesion molecule, fusidic acid inhibits the 
leukocyte rolling. Leukocyte rolling is part of the process of 
leukocyte extravasation into inﬂ  amed sites. This can result 
in the reduction of tissue injury and inﬂ  ammation associated 
with C. difﬁ  cile (Barreto et al 2007). The pharmacodynamics 
of fusidic acid were compared to that of metronidazole and 
vancomycin. The conclusions were that fusidic acid has the 
longest postantibiotic effect and postantibiotic sub-minimum 
inhibitory concentration compared to the other two antibiotics 
but that the greatest bacterialcidal effect was with metroni-
dazole (Odenholt et al 2007). The ﬁ  rst non-blinded study 
establishing the response of fusidic acid, when treating CDI, 
was reported by Cronberg et al (1984).
Wenisch et al (1996) conducted a prospective, random-
ized comparative study of ﬁ  rst episode CDI with fusidic 
acid, metronidazole, vancomycin, and teicoplanin. The 
deﬁ  nition of clinical cure was the lack of the following 
symptoms; loose stools, gastrointestinal symptoms or fever 
and the normalization of C-reactive protein and leukocyte 
counts. If the diarrhea persisted after 6 days, the treatment 
was deﬁ  ned as clinical failure. Clinical cure with fusidic 
acid was 93% (27/29 patients), metronidazole was 94% 
(29/31), vancomycin was 94% (29/31) and teicoplanin was 
96% (27/28) (p   0.05). Recurrence of symptoms was 28% 
with fusidic acid, 16% with metronidazole, 16% with vanco-
mycin and 7% with teicoplanin. The authors concluded that 
although fusidic acid had a high clinical cure rate, it also had 
the highest rate of recurrence and adverse effects, especially 
gastrointestinal discomfort (31%).
Fusidic acid was compared to metronidazole in treating 
the first episode of CDI in a double-blind randomized Therapeutics and Clinical Risk Management 2008:4(5) 956
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trial (Wullt and Odenholt 2004). The cure rate at the ﬁ  rst 
follow-up clinic visit was 83% with fusidic acid as compared 
to 93% with metronidazole (p = 0.116). The recurrence of 
symptoms was 27% with fusidic acid and 29% with metro-
nidazole while the reappearance of the C. difﬁ  cile toxin was 
13% with fusidic acid and 10% with metronidazole. The 
evaluation of symptoms and presence of toxin was done on 
days 35–40 after receiving the medications.
The use of fusidic acid for CDI was reviewed in three 
patients with ulcerative colitis, one patient with Crohn’s 
disease and one patient who was later diagnosed with Crohn’s 
disease (Bektas et al 2007). All of the patients received 
fusidic acid at 1,500 mg/day orally for 10 days. Four of the 
ﬁ  ve patients had been previously treated with metronidazole. 
The C. difﬁ  cile toxin A was negative in all of the cases on 
day 10 along with clinical symptoms. No recurrences were 
documented.
Teicoplanin
Structurally related to vancomycin, teicoplanin is a non-
absorbable glycopeptide antibiotic (Wistrom 1994; Citron 
et al 2003). Teicoplanin has exhibited lower minimal 
inhibitory concentrations against C. difﬁ  cile compared to 
vancomycin. A previous clinical trial resulted in a high 
initial cure rate with teicoplanin but 33% of the patients had 
clinical recurrence of CDI and bacteriological elimination 
rate at 4 weeks was only 59% (Wistrom 1994). A more recent 
clinical study completed by Wenisch et al (1996) compared 
teicoplanin to fusidic acid, metronidazole and vancomycin 
(Wenisch et al 1996). The results as previously discussed, 
revealed that teicoplanin was promising with a clinical cure 
rate of 96% and a recurrence rate of 7%.
Rifampin
As an anti-tubercular antibiotic, rifampin also has dem-
onstrated in vitro activity against C. difﬁ  cile (Fekety et al 
1983; Buggy et al 1987). High rifampin concentrations in 
the intestinal lumen have been reported but concentrations 
in the stool were not documented (Fekety et al 1983).
A prospective, single-blinded, randomized study of 
39 hospitalized patients with CDI, were given either metroni-
dazole 500 mg three times a day for 10 days or metronidazole 
with rifampin 300 mg twice a day for 10 days (Lagrotteria 
et al 2006). A clinical cure was if the patient was asymp-
tomatic during the treatment course or had a microbiological 
response. The group receiving metronidazole with rifampin 
had a clinical cure rate of 63% as compared to metronida-
zole at 65% (p = 0.91). The metronidazole and rifampin 
group had a 17% rate of laboratory-conﬁ  rmed relapse, while 
metronidazole was 31%. The authors halted the study early 
due to 6 deaths in the metronidazole and rifampin treatment 
group and one death in the metronidazole treatment group. 
The high mortality rate was attributed to the enrollment 
of elderly patients with numerous comorbidities such as 
diabetes, renal failure, cancer, and heart disease. The authors 
concluded that rifampin does not have a routine role as an 
adjunct to metronidazole in the treatment of hospitalized CDI 
due to a low cure rate.
Toxin-binding agents
Cholestyramine/colestipol
Cholestyramine and colestipol have been shown to bind 
C. difﬁ  cile toxins A and B in vitro and also vancomycin 
(Taylor and Bartlett 1980). Several case reports exist of 
both pediatric and adult patients who had several relapses 
and failed to respond to traditional treatments that were 
successfully treated with extended courses of cholestyramine 
(Kunimoto and Thomson 1986; Pruksananonda and Powell 
1989; Moncino and Falletta 1992). However, a randomized 
in vivo controlled trial of colestipol failed to show any impact 
on the fecal excretion of C. difﬁ  cile or its toxin from patients 
(Mogg et al 1982).
Tolevamer
Tolevamer, formerly known as GT160-246 and GT267-004, is 
an investigational styrene sulfonate polymer that has the abil-
ity to non-covalently bind C. difﬁ  cile toxins A and B (Braunlin 
et al 2004). The active ingredient is poly (4-styrenesulfonate) 
that contains as counter ions either 100% sodium (tolevamer 
sodium) or a combination of 63% sodium and 37% potas-
sium (tolevamer potassium-sodium) (Barker et al 2006). In 
animal studies, tolevamer was compared to cholestyramine 
in reducing ﬂ  uid accumulation caused by toxin A in rat ileal 
loops and mortality rates in a hamster model (Kurtz et al 
2001). Tolevamer was found to be at least 80 times more 
effective at inhibiting the ﬂ  uid accumulation due to toxin 
A and 16 times more effective at blocking intestinal perme-
ability compared to cholestyramine in the rat model. This 
study also found that 80% of tolevamer and 10% of chole-
styramine treated hamsters were protected from mortality 
due to C. difﬁ  cile infection.
Louie and colleagues compared tolevamer sodium with 
vancomycin in mild to moderate CDI in a Phase II clinical 
trial involving 289 patients (Louie et al 2006). Patients 
received either vancomycin 125 mg per day for 10 days or 
tolevamer 1 g 3 times a day or 2 g 3 times per day for 14 days. Therapeutics and Clinical Risk Management 2008:4(5) 957
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The primary end point was time to resolution of diarrhea 
which was deﬁ  ned as the ﬁ  rst of 2 consecutive days when 
the patient had  2 stools which were loose or watery or if 
the patient had hard or formed stools. Non-inferiority was 
deﬁ  ned as 2 days or less difference in resolution of diarrhea. 
In the per protocol group, tolevamer 6 g per day group was 
found to be non-inferior to vancomycin (p = 0.02). The most 
common side effect in this study was hypokalemia.
A Phase III clinical trial of more than 1,100 patients 
compared tolevamer to standard treatment (Genzyme 2007a; 
Genzyme 2007b; Genzyme 2007c). The study was a non-
inferiority trial of tolevamer potassium-sodium (GT267-004) 
compared to vancomycin and metronidazole. In a press release 
by Genzyme, the company stated that tolevamer did not 
prove to be non-inferior to vancomycin (Genzyme 2007c). 
Genzyme also noted that they expected results of a second 
Phase III clinical trial late in 2007. Currently, no clinical trials 
for tolevamer use in CDI could be identiﬁ  ed.
Immune-modifying agents
Monoclonal antibodies
Research has begun on human monoclonal antibodies 
directed against C. difﬁ  cile toxins A or B and the impact this 
may have on CDI (Babcock et al 2006). Based on animal 
data, two antibodies are being explored in clinical trials. 
CDA1 is directed against toxin A and MDX-1388 is directed 
against toxin B. Currently a Phase II study is being conducted 
to evaluate if the addition of the human monoclonal 
antibodies GS-CDA1 and MDX-1388 to standard treat-
ment for CDI reduces the risk of recurrent CDI compared to 
standard treatment plus placebo (University of Massachusetts 
2007). Patients will receive a single intravenous solution of 
GS-CDA1 combined with MDX-1388 or placebo (normal 
saline). The study plans to enroll 100 patients in each of the 
study arms.
Immunization
High levels of anti-toxin A IgG are associated with protection 
against CDI (Aboudola et al 2003). An anti-C. difﬁ  cile toxoid 
has been developed to determine if it is possible to induce an 
immune response in patients with multiple episodes of recur-
rent CDI (Sougioultzis et al 2005). Sougioultzis et al (2005) 
evaluated 3 patients with recurrent CDI treated with 4 doses 
of intramuscular C. difﬁ  cile toxoid vaccine (days 0, 7, 28, 56) 
and oral vancomycin daily until the day of the last dose of 
vaccine. Vancomycin doses ranged from 125 mg twice daily 
to 250 mg 4 times a day. The vaccine consisted of formalin-
detoxiﬁ  ed C. difﬁ  cile toxins A and B which was believed to 
induce anti-C. difﬁ  cile toxin IgG. In 2 of the 3 subjects, serum 
IgG antitoxin antibodies increased and all three subjects were 
able to stop vancomycin and remain disease free. Prior studies 
with this vaccine in healthy individuals found it to be well 
tolerated and able to produce antibody response (Kotloff et al 
2001; Aboudola et al 2003).
Results of a phase I trial of the vaccine containing 
inactivated C. difﬁ  cile toxins A and B were recently reported 
(Acambis 2007). This study found that four doses of the 
vaccine were well tolerated and produced an immune response 
in young healthy adults (Acambis 2006, 2008). The company 
stated that the majority of the side effects seen in the trial were 
similar to most intramuscular vaccine injections (pain, redness, 
and mild tenderness at the site of injection, and headache). 
A second phase I trial in patients 65 and older also found 
the vaccine to be well tolerated and to produce an immune 
response at various doses (Acambis 2008). In December of 
2007, Acambis reported that it had completed work on refor-
mulating the vaccine to improve stability over the vaccine 
used in the Phase 1 trials (Acambis 2007). They plan to begin 
a proof-of-concept study by the end of 2008.
Ghose and colleagues (2007) found that transcuta-
neous immunization with formalin-treated C. difficile 
toxin A resulted in anti-C. difﬁ  cile toxin A IgG and IgA 
responses in serum and anti-C. difﬁ  cile toxin A IgA in stool 
in mice (Ghose et al 2007). These ﬁ  ndings suggest that 
transcutaneous administration may be a viable option.
Immune globulin
Intravenous immune globulin (IVIG) has been documented 
as a therapeutic tool for the treatment of CDI in several case 
reports. Juang et al (2007) conducted a retrospective analy-
sis of patients who had severe C. difﬁ  cile positive disease 
during a 2-year time frame (Juang et al 2007). They identiﬁ  ed 
79 patients of which 18 had received IVIG in addition to stan-
dard therapy and matched them with 18 patients who had not 
received IVIG. IVIG was given at a dose of 200–300 mg/kg 
for a single dose. They did not ﬁ  nd a beneﬁ  cial response in 
patients who were treated with IVIG compared to standard 
therapy alone in the primary endpoints of all-cause mortality, 
length of stay or colectomies. This data is in conﬂ  ict with 
many case reports of success with IVIG therapy. Leung et al 
(1991) was one of the ﬁ  rst to report the successful use of IVIG 
400 mg/kg every 3 weeks in 6 children with relapsing CDI 
(Leung et al 1991). A retrospective review of 14 patients with 
severe, refractory, recurrent C. difﬁ  cile found that IVIG may 
be effective in this group (McPherson et al 2006). Patients 
received 1 to 5 courses of standard antibiotics prior to IVIG Therapeutics and Clinical Risk Management 2008:4(5) 958
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therapy. Doses of IVIG ranged from 150 to 400 mg/kg. 
Nine of the 14 patients had resolution of diarrhea, 1 had a 
partial response but died later after a recurrence and 4 died 
of other causes. Wilcox (2004) reported a series of 5 cases 
of CDI treated with IVIG in doses of 300–500 mg/kg for 
1, 2, or 6 doses. Of the 5 patients, 3 were considered suc-
cessfully treated; however, 1 did relapse within 6 weeks 
(Wilcox 2004). Beales (2002) reported successful treatment 
of 4 cases of refractory recurrent CDI with IVIG 400 mg/kg 
given twice, 21 days apart along with a tapering dose of 
vancomycin (Beales 2002). Several other individual case 
reports also reported successful treatment with varying 
regimens involving IVIG (Salcedo et al 1997; Murphy et al 
2006; Hassoun and Ibrahim 2007).
Despite multiple case reports of successful treatment 
with IVIG, good sound clinical trials are lacking and thus 
make it difﬁ  cult to recommend this for treatment of CDI at 
this time. High cost and low product availability also limit 
the potential use of this therapy.
Colostrum
Human colostrum has been found to have neutralizing 
activity against C. difficile toxins A and B and thus is 
thought to potentially protect newborns against these toxins 
(Wada et al 1980; Kim et al 1984; Dallas and Rolfe 1998). 
In recent years technology has allowed the development of 
“immune milk” from bovine colostrum (Kelly et al 1997). 
Cows can be immunized with speciﬁ  c pathogens or anti-
gens to produce colostrum that is higher in concentration of 
speciﬁ  c antibodies against those pathogens. Fractionation 
techniques have also been developed that allow isolation 
of immunoglobulins (Ig) from bovine colostrum and milk. 
IgG immunoglobulins are the predominate immunoglobulins 
in bovine colostrum (92%). IgM and IgA are also found in 
bovine colostrum. Animal models have found both protec-
tion from CDI and treatment of CDI with IgG concentrate 
from colostrum of hyperimmunized cows (Lyerly et al 1991; 
Kelly et al 1996). Warny et al (1999) were able to prove 
that bovine immunoglobulin concentrate containing high 
concentrations of IgG from colostrum of cows immunized 
against C. difﬁ  cile resisted digestion and inactivation in the 
upper gastrointestinal tract of humans (Warny et al 1999). 
This ﬁ  nding is important since toxin-neutralizing activity in 
the human colon is needed to have therapeutic beneﬁ  t. Kelley 
and colleagues (1997) also found data to support that a similar 
bovine immunoglobulin concentrate when taken orally by 
humans had the ability to neutralize activity of C. difﬁ  cile 
toxins A and B in their stools (Kelly et al 1997).
Whey protein concentrate
More recent studies of milk-derived preparations have 
centered on whey protein concentrates (van Dissel et al 2005; 
Numan et al 2006; Young et al 2007). Anti-C. difﬁ  cile whey 
protein concentrate (anti-CD-WPC) is made from mature 
milk (immune milk), not colostrum. In mature bovine milk 
IgA is the predominate immunoglobulin with lesser amounts 
of IgG and IgM. To produce anti-C. difﬁ  cile whey protein, 
milk is collected from cows that have been immunized 
against C. difﬁ  cile to produce immunoglobulins which are 
primarily of the IgA class. Anti-CD-WPC has been found 
to decrease relapse in patients with CDI when given after 
a course of standard antibiotics in two clinical trials (Van 
Dissel et al 2005; Numan et al 2006). In both trials whey 
protein concentrate 40% was used at a dose of 5 g (added to 
uncarbonated mineral water) three times a day for 14 days 
starting after patients had completed at least a 10-day course 
of metronidazole and/or vancomycin. The safety of anti-
CD-WPC was also evaluated in clinical trials and based on 
the data collected the product was well tolerated (Numan 
et al 2006; Young et al 2007).
Probiotics
CDIs are frequently attributed to antibiotics altering the 
normal gut ﬂ  ora thus allowing C. difﬁ  cile to ﬂ  ourish (Katz 
2006). The World Health Organization and Food and Agri-
cultural Organization deﬁ  ne probiotics as, “live microorgan-
isms which when administered in adequate amounts confer 
a health beneﬁ  t on the host” (FAO and WHO 2002, p 8). 
Probiotics serve as a potential method of restoring normal 
microbes in the gastrointestinal tract, which theoretically 
prevents or treats CDIs. Bacterial strains of Lactobacillus and 
Biﬁ  dobacterium and the yeast Saccharomyces are commonly 
utilized probiotics and have been used for the prevention and 
treatment of CDI (Boyle et al 2006; Katz 2006).
Overall reviews of the studies analyzing lactobacillus for 
CDI determined there are limited, inconclusive results on 
its effectiveness for preventing or treating CDI and suggest 
more clinical studies are needed (Katz 2006; Segarra-
Newnham 2007). Recently a randomized double-blind, 
placebo controlled study by Hickson et al (2007) further 
analyzed the effectiveness of lactobacillus as a prophylactic 
agent. Although the primary outcome of the study was the 
prevention of antibiotic associated diarrhea, the prevention 
of CDI was included as a secondary outcome. One hundred 
ﬁ  fteen hospitalized patients over the age of 50 who were 
receiving antibiotics were included in the ﬁ  nal analysis. The 
probiotic was administered as a 100 g liquid given twice daily Therapeutics and Clinical Risk Management 2008:4(5) 959
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and included Lactobacillus casei, Lactobacillus bulgaricus, 
and Streptococcus thermophilus. Probiotic administration 
began within 2 days of antibiotic therapy and continued 
for 7 days after antibiotics were discontinued. The study 
found an absolute risk reduction of 17% for the prevention 
of CDI, which was statistically signiﬁ  cant (p = 0.001). The 
estimated the cost of preventing one case of CDI secondary 
to antibiotic use was estimated at US$120 (£60; €89) and the 
authors concluded that regular use could result in signiﬁ  cant 
cost savings. These results are potentially promising, how-
ever the study was criticized for excluding patients taking 
clindamycin, cephalosporins and aminopenicillins, all 
antibiotics associated with a high risk of causing C. difﬁ  cile 
(Billyard 2007).
Although there are no controlled studies supporting 
Saccharomyces for the primary prevention of CDI, two 
randomized controlled trials support its use for recurrent 
CDI (McFarland et al 1994; Surawicz et al 2000). McFarland 
and colleagues (1994) conducted a randomized, placebo-
controlled trial utilizing S. boulardii 500 mg twice daily 
in 124 patients with active CDI (McFarland et al 1994). 
Approximately half (n = 60) of the patients had at least one 
prior CDI. Patients were also treated with metronidazole 
and/or vancomycin, with the S. boulardii therapy beginning 
within four days of the start of antibiotics. Patients were 
excluded if they had acquired immunodeﬁ  ciency syndrome or 
if they were immunosuppressed secondary to chemotherapy 
within the past 3 months. CDI recurrence rates were followed 
for 4 weeks after discontinuing the S. boulardii. Overall the 
treatment failure rate was 26.3% in the S. boulardii group 
vs 44.8% in the placebo group (p = 0.05). Upon further 
analysis researchers discovered that the signiﬁ  cant difference 
occurred in patients with at least one previous episode of 
CDI. In the patients with at least one prior CDI, 34.6% of the 
S. boulardii treatment group failed therapy versus 64.7% of 
placebo patients (p = 0.04). Of the patients being treated for 
their ﬁ  rst CDI, 19.3% failed S. boulardii treatment compared 
to 24.2% of placebo treated patients (p = 0.86). Although the 
treatment groups were small, this data suggests that patients 
experiencing at least 1 recurrent episode of CDI may beneﬁ  t 
from S. boulardii treatment.
Surawicz et al (2000) also conducted a random-
ized, double-blind, placebo controlled study utilizing 
S. boulardii for the treatment of recurrent CDI (n = 168) 
(Surawicz et al 2000). S. boulardii 500 mg BID or placebo 
was administered in addition to either metronidazole 1 g 
daily, vancomycin 500 mg daily, or vancomycin 2 g daily. 
S. boulardii was started on day 7 of the 10 day course of 
antibiotic and continued for a total of 28 days. Results of 
the study showed that patients treated with S. boulardii in 
addition to vancomycin 2 g daily had a 16.7% recurrence 
rate versus a 50% recurrence rate in the patients treated with 
vancomycin 2 g daily and placebo (p = 0.05). S. boulardii 
did not signiﬁ  cantly decrease the recurrence rate in either 
the vancomycin 500 mg daily group or the metronidazole 
group. A limitation to the results of this trial included the 
small number of patients (n = 32) included in the vancomycin 
2 g daily group.
The use of probiotics presents several potential concerns. 
Probiotics are usually considered dietary supplements and 
do not undergo as rigorous of testing compared to pharma-
ceutical agents (Boyle et al 2006). Therefore the assurance 
of purity, amount, and safety of the probiotics may be in 
question. In certain countries, regulation of these products 
occurs by varying governing organizations if the product is 
marketed for a speciﬁ  c health beneﬁ  t or use. Side effects 
of Lactobacillus and Biﬁ  dobacterium include bloating and 
ﬂ  atulence, which may be a transient effect of the probiotics 
eliminating the infectious bacteria (Karpa 2007). S. boulardii 
has been associated with constipation and increased thirst 
(McFarland et al 1994).
Bacteremia and endocarditis caused by Biﬁ  dobacteria and 
Lactobacillus have been reported and S. boulardii, is a rare 
cause of fungemia (Borriello et al 2003; Segarra-Newnham 
2007). While infections may be caused by these organisms, 
there are no data stating the risk of developing an infection 
secondary to consuming lactobacillus or biﬁ  dobacteria is 
any higher than the risk of infection due to a commensal 
organism (Borriello et al 2003). The overall reported risk of 
bacteremia due to these organisms is less than one case per 
one million people. A study in Finland demonstrated that 
increased consumption of lactobacilli was not associated 
with an increase in blood stream infections (Salminen 
et al 2002).
Despite the reports demonstrating the safety of probiotics, 
there are several case reports of Lactobacillus infections 
associated with probiotic use and even more reports of 
Saccharomyces fungemia related to consumption of 
S. boulardii (Muñoz et al 2005; Boyle et al 2006). These 
infections have occurred in immunocompromised, critically 
ill, or in patients with a chronic disease or debilitation, and no 
reports have associated these agents with causing infections in 
healthy individuals (Boyle et al 2006). A review of 60 cases of 
Sacchromyces fungemia showed 26 of the cases were directly 
associated with the administration of S. boulardii (Muñoz 
et al 2005). The majority of these cases involved critically Therapeutics and Clinical Risk Management 2008:4(5) 960
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ill patients, which calls into question the safety of this yeast 
in the critically ill or immunosuppressed population.
The reported infections associated with probiotics 
did not necessarily involve patients utilizing the therapy 
speciﬁ  cally for C. difﬁ  cile. However, the rare potential for 
infection needs to be considered given that patients who are 
afﬂ  icted with C. difﬁ  cile frequently have a chronic disease 
or may be immunocompromised. Although the case reports 
suggest the immunocompromised are at risk there are studies 
demonstrating the safe use of lactobacillus in transplant 
patients as well as those with documented HIV (Rayes et al 
2002; Salminen et al 2004). Infections secondary to the use 
of Biﬁ  dobacterium have not been reported, which may reﬂ  ect 
a safer bacteria or its relatively lower use rate in marketed 
products compared to lactobacillus (Boyle et al 2006).
Fecal transplantation
Aas et al (2003) describe a retrospective cases series of 
18 patients receiving stool transplant for the treatment of 
recurrent CDI. This method has been proposed to restore 
bacterial ﬂ  ora and reduce the growth of C. difﬁ  cile. The 
18 patients reviewed had a range of two to seven positive 
C. difﬁ  cile toxin tests prior to the transplant, and had received 
an average of 3.2 courses of antibiotic treatments consisting 
of metronidazole and/or vancomycin. The average time 
between the diagnosis of CDI and fecal transplantation 
ranged from 25 to 497 days. The fecal transplant was admin-
istered via a nasogastric tube and the details of the preparation 
and administration are described in the report. Of note all 
patients were treated with vancomycin 250 mg every 8 hours 
starting 4 days prior to transplant and discontinued the night 
before the procedure. Of the 18 patients receiving the trans-
plant, 15 had a resolution of CDI. Thirteen of these patients 
tested negative for C. difﬁ  cile toxin with the other 2 patients 
reporting no diarrhea recurrence in the 3-month follow up. 
Of the 3 patients unsuccessfully treated, two patients died 
within 2 weeks of transplant with both patients having critical 
illnesses present at the time of transplantation. The remaining 
patient experienced a recurrent case of CDI conﬁ  rmed with 
a positive C. difﬁ  cile toxin test and was successfully treated 
with a 10-day course of vancomycin.
Although no adverse effects were reported with the 
stool transplants, the potential risk of acquiring a disease 
secondary to the transplant does exist (Aas et al 2003). In the 
study by Aas et al (2003), this risk was minimized by prefer-
ably obtaining stool donation from an individual with a close 
physical connection to the recipient. If a spouse or signiﬁ  cant 
other was not available then another family member or a 
healthy individual was utilized. All donors were screened for 
hepatitis, A, B, and C, HIV-1, HIV-2, syphilis, C. difﬁ  cile, and 
other gastrointestinal pathogenic bacteria, ova and parasites. 
The patient acceptability of such a procedure may also be 
in question. Currently the limited data available regarding 
stool transplant only warrant its use in severe, recurrent 
cases that are refractory to other therapies. If the patients 
experiencing these types of infections determine that the 
disease is signiﬁ  cantly impairing their quality of life then the 
idea of a stool transplant potentially providing a cure may 
be given serious consideration.
Surgery
Because of high mortality rates associated with severe 
CDI, surgical consultation is recommended. Indications for 
surgery as a treatment modality include toxic megacolon, 
bowel perforation, and colonic-wall thickening (Gerding 
et al 2008a.) Overall post-surgical mortality rates are 
often high, with total colectomy being reported to have a 
lower mortality rate than partial colon resection (Koss et al 
2006). A retrospective observational cohort trial of CDI 
patients was recently published which evaluated emergency 
colectomy versus medical therapy alone in those admit-
ted to the intensive care unit (Lamontagne et al 2007). In 
the trial, independent predictors of 30-day mortality were 
leukocytosis  50 × 109/L, lactate  5 mmol/L, age  75 
years of age, immunosuppression, and shock requiring 
vasopressors. After adjusting for these confounders, the trial 
showed a reduction of mortality in the surgical intervention 
group. Colectomy appeared to be most beneﬁ  cial in immu-
nocompetent patients, those with leukocytosis  20 × 109 L, 
those with a lactate level between 2.2 and 4.9 mmol/L, and 
patients age 65 years and greater.
Conclusion
Metronidazole and vancomycin have historically been 
regarded as the primary therapy options for C. difﬁ  cile infec-
tion. Metronidazole is still regarded as the agent of choice 
for initial therapy and ﬁ  rst recurrence for most patients 
with mild to moderate CDI. Vancomycin use should be 
minimized when possible over concerns related to vanco-
mycin-resistant enterococci and staphylococci, and relatively 
higher costs when compared to treatment with metronida-
zole. Vancomycin use is recommended for those that do 
not respond to metronidazole, have severe CDI, and those 
with multiple recurrences of CDI. Difﬁ  culty associated with 
treatment of severe CDI, multiple recurrences of CDI and 
the emergence of a hypervirulent strain of C. difﬁ  cile have Therapeutics and Clinical Risk Management 2008:4(5) 961
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led to investigation into new CDI treatments. If faced with 
CDI treatment dilemmas, clinicians should consider these 
therapies based on their pros and cons. As additional clinical 
data involving these alternative treatment options become 
available, modiﬁ  cations to treatment algorithms is likely.
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